2021
Alcohol Use and the Risk of Communicable Diseases
Morojele NK, Shenoi SV, Shuper PA, Braithwaite RS, Rehm J. Alcohol Use and the Risk of Communicable Diseases. Nutrients 2021, 13: 3317. PMID: 34684318, PMCID: PMC8540096, DOI: 10.3390/nu13103317.Peer-Reviewed Original ResearchConceptsCommunicable diseasesTreatment outcomesSevere acute respiratory syndrome coronavirus 2Respiratory infection/pneumoniaAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Alcohol useDisability-adjusted life yearsSyndrome coronavirus 2Poor treatment outcomesCOVID-19 infectionAlcohol use disorderGlobal health concernIndividual-level interventionsDifferent communicable diseasesTB deathsImmunodeficiency virusCoronavirus 2Severe illnessUse disordersPneumoniaHeavy drinkersLife yearsHIV researchTuberculosis
2020
Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib
Foss FM, Rubinowitz A, Landry ML, Isufi I, Gowda L, Seropian S, Perreault S, Shenoi SV. Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib. Clinical Lymphoma Myeloma & Leukemia 2020, 20: 720-723. PMID: 32727701, PMCID: PMC7316063, DOI: 10.1016/j.clml.2020.06.014.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImmunocompromised HostLymphoma, T-CellMaleMiddle AgedNitrilesPandemicsPneumonia, ViralPyrazolesPyrimidinesSARS-CoV-2Severity of Illness IndexTransplantation, HomologousTreatment OutcomeConceptsAllogeneic hematopoietic stem cell transplant patientsHematopoietic stem cell transplant patientsSevere acute respiratory syndrome coronavirus 2SARS coronavirus 2 (SARS-CoV-2) infectionSARS-CoV-2 pneumoniaAcute respiratory syndrome coronavirus 2Stem cell transplant patientsSARS-CoV-2 infectionRespiratory syndrome coronavirus 2Coronavirus 2 infectionCell transplant patientsCoV-2 infectionStem cell transplantationSyndrome coronavirus 2High death rateImmunocompromised stateJAK/STAT inhibitor ruxolitinibTransplant patientsCell transplantationCoronavirus 2Novel therapiesInhibitor ruxolitinibPatientsDeath rateRuxolitinib